| Primary |
| Pneumonia |
33.8% |
| Pneumonia Aspiration |
7.9% |
| Hypertension |
7.3% |
| Antibiotic Prophylaxis |
5.8% |
| Pyrexia |
5.0% |
| Ill-defined Disorder |
4.7% |
| Infection |
3.9% |
| Cellulitis |
3.7% |
| Urinary Tract Infection |
3.7% |
| Insomnia |
2.9% |
| Bronchitis |
2.6% |
| Drug Use For Unknown Indication |
2.6% |
| Cardiac Failure |
2.4% |
| Ileus |
2.4% |
| Interstitial Lung Disease |
2.1% |
| Peritonitis |
2.1% |
| Antibiotic Therapy |
1.8% |
| Appendicitis |
1.8% |
| Atrial Fibrillation |
1.8% |
| Epilepsy |
1.8% |
|
| Pneumonia |
12.4% |
| Interstitial Lung Disease |
10.2% |
| Rash |
7.5% |
| Renal Impairment |
7.0% |
| Shock |
5.9% |
| Stevens-johnson Syndrome |
5.4% |
| Anaphylactic Shock |
4.8% |
| Enterocolitis Haemorrhagic |
4.8% |
| Pruritus |
4.3% |
| Pyrexia |
4.3% |
| Renal Failure Acute |
4.3% |
| Toxic Epidermal Necrolysis |
4.3% |
| Rash Generalised |
3.8% |
| Toxic Skin Eruption |
3.8% |
| Eosinophilic Pneumonia |
3.2% |
| Hypotension |
3.2% |
| Blood Creatine Phosphokinase Increased |
2.7% |
| Laryngeal Oedema |
2.7% |
| Pathogen Resistance |
2.7% |
| Renal Failure |
2.7% |
|
| Secondary |
| Pneumonia |
19.8% |
| Drug Use For Unknown Indication |
16.3% |
| Pneumonia Mycoplasmal |
6.6% |
| Product Used For Unknown Indication |
6.6% |
| Pyrexia |
6.4% |
| Hypertension |
4.5% |
| Prophylaxis |
4.1% |
| Juvenile Arthritis |
3.5% |
| Abdominal Discomfort |
3.3% |
| Bronchitis |
3.1% |
| Liver Disorder |
3.1% |
| Nervous System Disorder |
3.1% |
| Pyelonephritis Acute |
2.9% |
| Infection Prophylaxis |
2.7% |
| Parkinson's Disease |
2.7% |
| Pneumonia Aspiration |
2.5% |
| Infective Tenosynovitis |
2.3% |
| Sepsis |
2.3% |
| Induction Of Anaesthesia |
2.1% |
| Infection |
1.9% |
|
| Vomiting |
9.3% |
| Toxic Epidermal Necrolysis |
8.4% |
| Interstitial Lung Disease |
6.5% |
| Rash |
6.5% |
| Staphylococcal Infection |
6.5% |
| Hepatic Function Abnormal |
5.6% |
| International Normalised Ratio Abnormal |
5.6% |
| Renal Impairment |
5.6% |
| Drug Ineffective |
4.7% |
| Idiopathic Thrombocytopenic Purpura |
4.7% |
| Pneumonia Aspiration |
4.7% |
| Sepsis |
4.7% |
| Agranulocytosis |
3.7% |
| Drug Eruption |
3.7% |
| Pneumonia |
3.7% |
| Rash Pustular |
3.7% |
| Toxic Skin Eruption |
3.7% |
| Eczema |
2.8% |
| Eosinophil Count Increased |
2.8% |
| Erythema Multiforme |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.7% |
| Drug Use For Unknown Indication |
13.5% |
| Prophylaxis |
9.1% |
| Pneumonia |
7.2% |
| Multiple Myeloma |
6.4% |
| Hypertension |
5.8% |
| Pain |
5.1% |
| Non-small Cell Lung Cancer |
3.2% |
| Bacterial Infection |
2.9% |
| Diabetes Mellitus |
2.3% |
| Infection |
2.2% |
| Pyrexia |
2.1% |
| Asthma |
1.9% |
| Infection Prophylaxis |
1.7% |
| Cardiac Failure |
1.6% |
| Breast Cancer |
1.5% |
| Anaemia |
1.5% |
| Antibiotic Prophylaxis |
1.5% |
| Constipation |
1.4% |
| Insomnia |
1.3% |
|
| Vomiting |
14.0% |
| White Blood Cell Count Decreased |
13.7% |
| Pneumonia |
9.3% |
| Respiratory Failure |
6.3% |
| Weight Decreased |
6.0% |
| Rhabdomyolysis |
5.7% |
| Interstitial Lung Disease |
4.2% |
| Pyrexia |
4.2% |
| Renal Impairment |
4.2% |
| Wound Drainage |
4.2% |
| Convulsion |
3.6% |
| Sepsis |
3.3% |
| Hepatic Function Abnormal |
3.0% |
| Urinary Tract Infection |
3.0% |
| Pain |
2.7% |
| Staphylococcal Infection |
2.7% |
| Therapeutic Response Decreased |
2.7% |
| Wound Complication |
2.7% |
| Respiratory Arrest |
2.4% |
| Thrombocytopenia |
2.4% |
|
| Interacting |
| Product Used For Unknown Indication |
80.4% |
| Infection |
10.7% |
| Bronchopneumonia |
7.1% |
| Analgesic Therapy |
1.8% |
|
| Drug Interaction |
50.0% |
| International Normalised Ratio Increased |
33.3% |
| Agranulocytosis |
16.7% |
|
